Clinical trial
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated…
NCT00140387 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00140387 |
|---|---|
| Title | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) |
| Official title | Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) in Hormone-naïve Prostate Cancer Patients |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
| Enrollment | 20 |
| Start date | May 1, 1999 |
| Completion | Mar 1, 2001 |
| First posted | Sep 1, 2005 |
| Last update posted | Sep 1, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: